Scarica l'app Stockscreener
99.75
2.19%
-2.23
Pre-mercato:
101.18
1.43
+1.43%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Incyte Corp Borsa (INCY) Ultime notizie
Incyte slides as investors digest updated INCA033989 (mutCALR) data and a cautious analyst take - Quiver Quantitative
Incyte Corp. stock underperforms Monday when compared to competitors - MarketWatch
BMO reiterates Incyte stock Underperform on ET/MF trial data - Investing.com UK
Key deals this week: GSK, Incyte, Ingredion, OpenAI, and more - MSN
BMO reiterates Incyte stock Underperform on ET/MF trial data By Investing.com - Investing.com Canada
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review - Yahoo Finance
Stifel reiterates Incyte stock rating on drug trial data review - Investing.com
Stifel reiterates Incyte stock rating on drug trial data review By Investing.com - Investing.com Canada
Incyte nears $2B deal for blood disorder drug developer Star Therapeutics: FT - MSN
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival - BioSpace
Incyte (INCY) Reports Promising Phase 2 Results for Zilurgiserti - GuruFocus
Incyte (INCY) Shows Promising Phase 3 Trial Results for Tafasita - GuruFocus
Incyte (INCY) Reveals Promising Results for Novel Antibody in Cl - GuruFocus
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva - Yahoo Finance Singapore
Key deals this week: GSK, Incyte, Ingredion, OpenAI, and more (BCS:NYSE) - Seeking Alpha
Incyte to buy Vega Therapeutics in hematology deal worth up to $2B - MSN
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia - Business Wire
Incyte Stock (US45337C1027): Ownership shifts and pipeline focus keep shares in view - AD HOC NEWS
Lymphoma drug combo cut risk of progression or death 25% - Stock Titan
Incyte reports positive Phase 3 trial results for lymphoma drug - Investing.com
Rx Rundown: Incyte, Parabilis Medicines, Pfizer and more - Medical Marketing and Media
Incyte Stock (US45337C1027): Quarterly trends and sector context for US investors - AD HOC NEWS
Incyte Buys Vega To Add Late Stage Von Willebrand Disease Opportunity - Yahoo Finance
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Incyte Nears Buy Point As $1.25 Billion Acquisition Expands Offerings - Investor's Business Daily
Incyte Corporation $INCY Shares Bought by Illinois Municipal Retirement Fund - MarketBeat
Incyte bolsters haematology portfolio in $2bn Vega buyout - MSN
Incyte Buyout Bet: The $2 Billion Move Investors Can’t Ignore! - Smartkarma
Daily Brief Health Care: Laurus Labs, Ascendis Pharma, GSK , Incyte Corp, Insmed Inc, Johnson & Johnson, Kardigan, LogicMark, Parabilis Medicines, Solventum and more - Smartkarma
Incyte to Acquire Vega Therapeutics from Star Therapeutics for Up to $2 Billion - Global Legal Chronicle
Why Incyte (INCY) Stock Is Up Today - Yahoo Finance
Incyte (INCY) director Jacqualyn Fouse awarded RSUs and 6,111 stock options - Stock Titan
H.C. Wainwright raises Incyte stock price target to $140 on Vega deal - Investing.com
Incyte to Buy Vega Therapeutics in Hematology Deal Worth Up to $2B - Yahoo Finance
INCY Maintains Rating by HC Wainwright & Co. -- Price Target Rai - GuruFocus
Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster PotentialIncyte (NASDAQ:INCY - Benzinga
HC Wainwright Issues Positive Forecast for Incyte (NASDAQ:INCY) Stock Price - MarketBeat
Incyte to acquire blood disorder drug candidate for $2B - Delaware Business Times
Stifel reiterates Incyte stock Buy rating on VGA039 acquisition - Investing.com
Stifel reiterates Incyte stock Buy rating on VGA039 acquisition By Investing.com - Investing.com UK
Incyte Corp at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Natixis Advisors LLC Purchases 10,795 Shares of Incyte Corporation $INCY - MarketBeat
Incyte Corporation (INCY) Announces Acquisition of Vega Therapeu - GuruFocus
Incyte makes $2 billion bet on bleeding disorder drug ahead of Jakafi patent cliff - MSN
In its largest M&A deal, Incyte adds late-stage bleeding candidate via Vega buy - BioCentury
Goodwin, Fenwick Guide Incyte-Vega Deal Worth Up To $2B - Law360
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Three Bay Area biotech startups ink big-company deals potentially totaling $5 billion - The Business Journals
Oppenheimer raises Incyte stock price target on Vega acquisition By Investing.com - Investing.com Australia
Oppenheimer raises Incyte stock price target on Vega acquisition - Investing.com
Incyte To Acquire Vega Therapeutics For Up To $2 Billion To Expand Hematology Portfolio Into Bleeding Disorders - Pulse 2.0
Incyte (INCY) to Acquire Vega Therapeutics for $1.25B - GuruFocus
Incyte to acquire Vega Therapeutics in deal valued at up to $2B - The Business Journals
Incyte Corporation (INCY) Vega Therapeutics, Inc.M&A CallSlideshow (NASDAQ:INCY) 2026-06-08 - Seeking Alpha
Incyte to acquire Star subsidiary Vega Therapeutics - The Pharma Letter
Incyte acquires Vega Therapeutics in $1.25 billion deal - grafa.com
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):